ADC Therapeutics. (ADCT) is scheduled to host a conference call today at 8:00 a.m. EST to provide an update on its LOTIS-7 trial.
LOTIS-7 is a Phase 1b open-label clinical trial evaluating the safety and efficacy of the company's drug ZYNLONTA in combination with Roche's cancer med COLUMVI in patients with relapsed or refractory diffuse large B-cell lymphoma. A combination of ZYNLONTA plus polatuzumab vedotin and ZYNLONTA plus mosunetuzumab will also be evaluated in this trial.
According to the LOTIS-7 trial results presented at the European Hematology Association 2025 Congress this June, ZYNLONTA in combination with COLUMVI demonstrated an overall response rate of 93.3% and a complete response rate of 86.7% across 30 efficacy evaluable relapsed or refractory diffuse large B-cell lymphoma patients.
ADCT closed Tuesday's trading at $4.60, up 8.49%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.